Extensive Stage Small Cell Lung Cancer Clinical Trials

186 clinical trials for Extensive Stage Small Cell Lung Cancer across international registries, including 42 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). — RECRUITING · PHASE3
• C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER — RECRUITING · PHASE3
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer — RECRUITING · PHASE3
• A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer — RECRUITING · PHASE1
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — RECRUITING · PHASE3
• Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) — RECRUITING · PHASE4
• Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) — RECRUITING · PHASE3
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — RECRUITING · PHASE3
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — RECRUITING · PHASE2
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — RECRUITING · PHASE3
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors — RECRUITING · PHASE1
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — RECRUITING · PHASE1
• A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) — RECRUITING
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy — RECRUITING · PHASE1
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC — RECRUITING · PHASE2
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) — RECRUITING · PHASE1
• A non-interventional study to assess the immune system activation of extensive stage small-cell lung cancer patients, at time of receiving first line standard immune-chemotherapy and at relapse — RECRUITING
• A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Treatment Phase. — RECRUITING · PHASE2
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC — RECRUITING · PHASE1
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer — RECRUITING · PHASE2
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC — RECRUITING · PHASE2
• Iadademstat + SBRT With Atezo in ES-SCLC — RECRUITING · PHASE1
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) — RECRUITING · PHASE2
• Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer — RECRUITING · PHASE2
• YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer — RECRUITING · NA
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) — RECRUITING · PHASE1
• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER — RECRUITING · PHASE1
• Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study of Ivonescimab in First-Line ES-SCLC — RECRUITING · PHASE2
• Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC — RECRUITING
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases — RECRUITING · PHASE2
• Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC — RECRUITING · PHASE2
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan — RECRUITING · PHASE4
• Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer — RECRUITING
• Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). — RECRUITING · PHASE2
• Second-line Immunotherapy for ES-SCLC — RECRUITING · NA
• Radiotherapy to All Residual Lesions After Chemoimmunotherapy — RECRUITING · PHASE1
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC — RECRUITING · PHASE2
• PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) — RECRUITING · NA
• A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer — TERMINATED · PHASE3
• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease — NOT_YET_RECRUITING · PHASE1
• A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive‑stage Small Cell Lung Cancer (ES‑SCLC) (IDeate-Lung03). — TERMINATED · PHASE2
• A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi 305) — TERMINATED · PHASE3
• Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer — OTHER
• Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310) — COMPLETED · PHASE1
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search